Stephen V. Liu, MD, Georgetown University

Articles

Rapid Readouts: Safety and Efficacy of Pralsetinib in Patients with Advanced RET Fusion-Positive Non-Small Cell Lung Cancer: Update from the ARROW trial

July 13th 2021

Stephen V. Liu, MD, presents data from the 2021 American Society of Clinical Oncology annual meeting on the updated results from the ARROW trial of pralsetinib in patients with RET fusion-positive non-small cell lung cancer.

Emerging Agents and Future of Small Cell Lung Cancer

April 2nd 2021

Jared Weiss, MD, and Stephen V. Liu, MD discuss treatment of small cell lung cancer and therapies in the pipeline.

Management of ES-SCLC: Second Line and Beyond

April 2nd 2021

Considerations for second-line treatment regimens, the role of immunotherapy in the relapsed/refractory setting, and using lurbinectedin for the management of ES-SCLC.

Using Trilaciclib for Treatment of ES-SCLC

April 2nd 2021

Stephen V. Liu, MD, and Jared Weiss, MD, share their thoughts on the impact of the recent approval of trilaciclib prior to platinum/etoposide-based chemotherapy for the treatment of ES-SCLC.

Standard of Care for ES-SCLC

March 25th 2021

Experts in thoracic oncology review data from the IMpower133 and CASPIAN trials as well as the use of chemotherapy with PD-L1 inhibitors for treatment-naïve ES-SCLC in clinical practice.

Staging for Small-Cell Lung Cancer

March 25th 2021

Insights on the differences between limited-stage and extensive-stage small-cell lung cancer and recent progress made with combination chemotherapy plus immunotherapy.